Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Response and Nippon Kayaku to develop PSA (prostate specific antigen) test:

This article was originally published in Clinica

Executive Summary

Response Biomedical and Japanese company Nippon Kayaku are to collaborate on developing a prostate cancer test for use on Response's quantitative, point-of-care RAMP diagnostic system. The Vancouver, British Columbia company has signed an agreement with the Japanese partner, based in Tokyo, to make a test for the prostate cancer marker prostate specific antigen (PSA). Nippon Kayaku will fund the development and Japanese regulatory submission of the PSA test and will have sales and distribution rights for the product in Japan. Response reserves rights for other markets. The company has already developed a number of tests for other medical conditions for use on the RAMP assay.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT070135

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel